| 1. |
- Garea-Rodríguez, Enrique, et al.
(författare)
-
Comparative analysis of the effects of neurotrophic factors CDNF and GDNF in a nonhuman primate model of Parkinson’s disease
- 2016
-
Ingår i: PLoS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 11:2, s. 1-21
-
Tidskriftsartikel (refereegranskat)abstract
- Cerebral dopamine neurotrophic factor (CDNF) belongs to a newly discovered family of evolutionarily conserved neurotrophic factors.We demonstrate for the first time a therapeutic effect of CDNF in a unilateral 6-hydroxydopamine (6-OHDA) lesion model of Parkinson’s disease in marmoset monkeys. Furthermore, we tested the impact of high chronic doses of human recombinant CDNF on unlesionedmonkeys and analyzed the amino acid sequence ofmarmoset CDNF. The severity of 6-OHDA lesions and treatment effects weremonitored in vivo using 123I-FP-CIT (DaTSCAN) SPECT. Quantitative analysis of 123I-FP-CIT SPECT showed a significant increase of dopamine transporter binding activity in lesioned animals treated with CDNF. Glial cell line-derived neurotrophic factor (GDNF), a well-characterized and potent neurotrophic factor for dopamine neurons, served as a control in a parallel comparison with CDNF. By contrast with CDNF, only single animals responded to the treatment with GDNF, but no statistical difference was observed in the GDNF group. However, increased numbers of tyrosine hydroxylase immunoreactive neurons, observed within the lesioned caudate nucleus of GDNF-treated animals, indicate a strong bioactive potential of GDNF.
|
|
| 2. |
|
|
| 3. |
- Helms, Gunther, et al.
(författare)
-
Excretion Rate and Distribution Volumes in Common Marmoset Monkeys After Slow and Fast Injection of Gadobutrol
- 2015
-
Ingår i: Proceedings of the International Society for Magnetic Resonance in Medicine Annual Meeting 2015. - 1545-4428. ; 23
-
Konferensbidrag (refereegranskat)abstract
- Common marmoset monkeys (Callithrix jacchus) are increasingly used in models of neurodegenerative diseases. Serial measurements of gadolinium excretion were performed using the dual flip angle method to map R1 on three animals in the wrist coil of a 3T whole-body system. R1 values were analyzed in a ROI in the straight sinus and fitted with a single compartment model. Slow injection of 0.3 mmol Gadovist per kg bodyweight (2 min duration) resulted in faster equilibration and excretion, as well as smaller distribution volumes than fast injection (15 sec). Slow injection and an equilibration delay of 15 minutes are recommended.
|
|
| 4. |
- Helms, Gunther, et al.
(författare)
-
Pharmacokinetics of the MRI contrast agent gadobutrol in common marmoset monkeys (Callithrix jacchus)
- 2016
-
Ingår i: Journal of Medical Primatology. - : Wiley. - 0047-2565. ; 45:6, s. 290-296
-
Tidskriftsartikel (refereegranskat)abstract
- Background: This study determined the pharmacokinetics of the contrast agent gadobutrol in marmosets by quantitative MRI to derive guidelines for neuroimaging protocols. Methods: Local concentrations of gadobutrol were determined from consecutive gradient echo-based mapping of the relaxation rate R1 on a clinical 3T MRI scanner. Half-time of renal elimination was measured after injection of a triple dose of gadobutrol (0.3 mmol/kg) into the saphenous vein. A first-order single-compartment model was fitted to the measured R1 values and verified by blood analysis. Results: Slow injection (1.5 minutes) resulted in an elimination half-time of 26±4 minutes. After bolus injection (15 seconds), elimination was much slower (62±8 minutes) with 45% larger distribution volumes. Importantly, more gadobutrol entered the cerebrospinal fluid. Conclusions: Slow injection and a latency of about 20 minutes are recommended to avoid extravasation. Application of a triple dose of gadobutrol compensates for the fast elimination in healthy marmosets.
|
|
| 5. |
|
|
